Table 2.
Univariate analysis of PFS and OS
| PFS | 95% CI | P-value | OS | 95% CI | P-value | |
|---|---|---|---|---|---|---|
| Gender | 0.06 | 0.12 | ||||
| Male | 2.5 | 1.4–3.6 | 5.2 | 3.2–5.7 | ||
| Female | 10.0 | 4.7–12.3 | 10.7 | 5.1–14.1 | ||
| Age, years | 0.13 | 0.21 | ||||
| >60 | 7.0 | 1.2–12.3 | 4.2 | 1.5–5.5 | ||
| ≤60 | 1.2 | 0.4–2.0 | 6.5 | 4.2–7.9 | ||
| PS | 0.07 | 0.09 | ||||
| 0–1 | 10.0 | 1.2–13.5 | 8.5 | 5.4–14.2 | ||
| 2 | 3.0 | 0.5–5.5 | 4.5 | 3.0–6.8 | ||
| Line of therapy | 0.43 | 0.31 | ||||
| Third–line | 2.5 | 0.0–8.4 | 7.2 | 3.8–10.5 | ||
| Further-line | 8.0 | 0.1–12.9 | 5.5 | 4.0–7.7 | ||
| Smoking history | 0.34 | 0.47 | ||||
| Yes | 2.5 | 1.5–3.5 | 5.5 | 3.0–8.5 | ||
| No | 8.0 | 5.2–10.8 | 7.8 | 6.0–10.5 | ||
| Histology | 0.36 | 0.17 | ||||
| Adenocarcinoma | 7.0 | 0.0–12.6 | 6.5 | 0.3–12.7 | ||
| Squamous cell | 1.9 | 0.0–5.0 | 4.3 | 2.1–8.5 | ||
| EGFR status | 0.25 | 0.87 | ||||
| Mutation | 4.4 | 0.6–4.8 | 7.0 | 5.0–9.5 | ||
| Wild-type | 4.0 | 1.0–6.0 | 5.5 | 4.0–6.5 | ||
| Prior treatment efficacy | 0.42 | 0.55 | ||||
| Responder | 4.6 | 1.2–6.2 | 7.5 | 3.5–10.0 | ||
| Nonresponder | 3.5 | 0.0–5.0 | 5.0 | 2.5–9.0 |
Abbreviations: PFS, progression-free survival; OS, overall survival; PS, performance status.